New hope for Tough-to-Treat lung cancer: major trial tests promising drug combinations
Disease control
Ongoing
This large, late-stage trial is comparing two experimental treatment approaches against standard chemotherapy for people whose small cell lung cancer has returned after initial treatment. About 705 patients will receive either a new drug called lurbinectedin alone, lurbinectedin …
Phase: PHASE3 • Sponsor: PharmaMar • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC